From disease modification to disease resolution

While conventional disease-modifying medicines can slow pathologic, symptomatic and functional decline, they cannot reverse disease and may suppress repair. Our approach has the potential to go beyond conventional disease modification by rebuilding damaged tissue to restore normal architecture. This could enable patients to not only reduce symptoms but also reverse their decline, resolving disease and regaining lost function.

Our groundbreaking products program disease resolution and offer novel treatments for a wide range of disorders. Our lead asset is in development for autoimmunity and fibrosis.